January 2, 2018: MedAware Secures Second Year of Funding Support from the Israel Innovation Authority
MedAware announced today that the company has recently received approval for its second year of funding from the Israel Innovation Authority. The financing grant is a clear indication of the Israeli government’s support for MedAware’s game-changing medication surveillance solutions, as well as the company’s technological progress, roadmap and market potential.
August 16, 2017: MedAware Raises $8 Million in Series A Funding to Eradicate Catastrophic Prescription Errors
MedAware today announced that the company has raised $8 million in Series A funding. Investors participating in the round included BD (Becton, Dickinson and Company), Gefen Capital, OurCrowd and Yingcheng City Fubon Technology Co. In addition, MedAware has received grants from Israel’s Innovation Authority and the BIRD Foundation, as well as from the European Commission as part of its Horizon2020 program, bringing the company’s total funding raised to date to $12 million.
August 2, 2017: MedAware CEO to Present How Machine Learning Can Eradicate Catastrophic Medication Errors at Allscripts Client Experience
To qualify the value of medication surveillance technology, Dr. Stein will present, “Leveraging Advanced Machine Learning to Eradicate Catastrophic Medication Errors” at Allscripts Client Experience (ACE) 2017, taking place on Tuesday, August 8 and Wednesday, August 9, 2017.
June 6, 2017: MedAware Extends North American Footprint with New Office Opening
MedAware today announced that the company has opened its North American headquarters in Stamford, CT. The Israeli-based startup’s U.S. operations will be led by Ori Karev who serves as the company’s chief business officer.
January 19, 2017: Harvard Research Shows New Technology Can Save Thousands of Lives a Year by Reducing Prescription Errors
MedAware is pleased to report today the findings of a landmark study carried out by Harvard Medical School. The study analysed records from almost 800,000 patients in order to assess the efficacy of MedAware’s innovative and unique solution, and the results have provided a comprehensive validation of MedAware’s disruptive solution.